This multicenter, randomized, single-blind study compared the efficacy and safety of a new, twice-daily formulation of
amoxycillin/
clavulanate (Augmenting) with the standard three-times-daily formulation. Children with a clinical diagnosis of acute
otitis media, aged between 2 months and 12 years, received either
amoxycillin/
clavulanate 45/6.4 mg/kg/day twice-daily (b.d.) (range 38.3/5.5-76.2/10.9 mg/kg/day) or
amoxycillin/
clavulanate 40/10 mg/kg/day three-times-daily (t.d.s.) (range 25/6.25-56/14 mg/kg/day) for 7 or 10 days. Patients were evaluated during
therapy (Days 3-5), at the end of
therapy (Days 7-12) and at follow-up (Days 38-42). At the end of
therapy, for the intent-to-treat and per-protocol populations, respectively, clinical success (cure) was achieved by approximately 94% of patients in both treatment groups. A successful bacteriological response at the end of
therapy (Visit 3) was documented in 7/9 patients (77.8%) in the twice-daily group and in 11/13 patients (84.6%) in the three-times-daily group. At follow-up (Visit 4), 93.3% of patients in the twice-daily group and 87.9% in the three-times-daily group continued to have a clinically successful response. Both treatment regimens were well tolerated, with most adverse events being of a mild-moderate and transient nature. The most common treatment-related adverse event was
diarrhea, occurring in 7.2% of patients in the twice-daily group and in 10.7% of the three-times-daily group. In total, 173 patients (82.8%) in the twice-daily group and 151 patients (73.3%) in the three-times-daily group were compliant with medication. In conclusion, this study confirms that b.d.
amoxycillin/
clavulanate is an effective treatment for pediatric acute
otitis media and demonstrates that the b.d. and t.d.s. formulations of
amoxycillin/
clavulanate produce equivalent efficacy. Furthermore, there was a trend towards a higher level of compliance and a lower incidence of
drug-related adverse events in the twice-daily compared with the three-times-daily treatment group.